FLUOXETINE IN THE TREATMENT OF OBESE TYPE-2 DIABETIC-PATIENTS

In a 12-month randomly allocated double-blind trial in 19 obese Type 2 diabetic patients, fluoxetine 60 mg daily compared to placebo produce d a significant fall in median body weight after 3 months (3.8 kg), 6 months (6.5 kg), 9 months (7.1 kg), and at 1 year (5.8 kg). Median fas ting blood glucose and HbA1c levels fell significantly after 3 months (1.9 mmol l-1 and 1.7 %, respectively) and 6 months (1.8 mmol l-1 and 1.7 %) but neither showed a significant difference to placebo after 9 or 12 months therapy with fluoxetine. There were no significant change s in serum cholesterol levels in the year but patients on fluoxetine s howed a significant fall in serum triglyceride level (0.5 mmol l-1) af ter 3 months therapy but not thereafter. Compared to placebo there was a significant fall in median energy intake on fluoxetine after 3 mont hs (257 kcal day-1) and 6 months (199 kcal day-1) but this difference was not significant at 9 or 12 months. There was also a significant fa ll in carbohydrate intake after 3 months (30 g day-1) and 6 months (23 g day-1) on fluoxetine as well as a significant fall in carbohydrate intake expressed as a percentage of the total daily energy intake; 5.9 % at 3 months, 6.1 % at 6 months, and 4.0 % at 9 months. There were n o significant effects on protein or fat intake except a significant in crease in the intake of fat expressed as a percentage of daily energy intake, 5.9 % after 6 months. Two of the nine patients on fluoxetine d ropped out of the study due to gastrointestinal side-effects. Fluoxeti ne might prove to be a useful adjunct therapy in obese Type 2 diabetic patients where short-term weight loss and fall in carbohydrate intake and an improvement in glycaemia are indicated.